Nir Kalkstein
Co-founder & CTO @ Medial EarlySign
Kfar Malal, Israel
Nir Kalkstein is an entrepreneur, a data scientist and a recognized expert in Big Data and machine learning algorithms. Nir co-founded Final, one of the most successful algo-trading companies worldwide. In 2009 He co-founded Medial with the vision of creating data-driven best-in-class predicative tools that provide physicians with actionableinsights to save lives. Nir has devoted significant intellectual and financial resources to support the ongoing success of the research for the Company, initially as the sole financier, and is committed to reinvesting his future profits into further research. Nir holds a BSc in Electrical Engineering from the Israeli Technion Institute of Technology.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Nir Kalkstein invests in
Stages Nir Kalkstein invests in
Countries Nir Kalkstein invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (100%)
- Machine Learning 2 (100%)
- Artificial Intelligence 2 (100%)
- Big Data 1 (50%)
- Health Diagnostics 1 (50%)
Stage
- Seed 1 (50%)
- Series B 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Medial EarlySign
|
Medial EarlySign develops an AI algorithmic platform for the discovery of clinical insights that indicate the likelihood of disease from basic medical information, such as blood test results, and other EMR data. Called AlgoMarkers, its predictive engines are built in collaboration with healthcare organizations, through the combination of 10s ofmillions of patient years-worth of data, clinical rigor and some of the most brilliant algorithmic minds. The company develops clinical decision support and population health solutions that can assist in the early prediction of clinical outcomes related to cancers, metabolic, immune and infectious diseases. These tools are designed to place at the fingertips of healthcare organizations only those insights that could prove critical in disease management and prevention empowering them with proactive, predictive and personalized care management capabilities | $30M / Series B / Mar 06, 2018 | |
Nucleai
|
Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies,licensing its research platform for internal use, and collaborating in biomarkers discovery projects. | $5M / Seed / Mar 05, 2018 |
Co-Investors
About Medial EarlySign
Medial EarlySign develops an AI algorithmic platform for the discovery of clinical insights that indicate the likelihood of disease from basic medical information, such as blood test results, and other EMR data. Called AlgoMarkers, its predictive engines are built in collaboration with healthcare organizations, through the combination of 10s ofmillions of patient years-worth of data, clinical rigor and some of the most brilliant algorithmic minds. The company develops clinical decision support and population health solutions that can assist in the early prediction of clinical outcomes related to cancers, metabolic, immune and infectious diseases. These tools are designed to place at the fingertips of healthcare organizations only those insights that could prove critical in disease management and prevention empowering them with proactive, predictive and personalized care management capabilities
Medial EarlySign Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Nir Kalkstein
Co-founder & CTO
|
|||
Avi Shoshan
Head of Data Science
|
|||
Darrell Atkin
Vice President Marketing
|
|||
Ori Geva
Co-founder & President of Commercial Strategy
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Nir Kalkstein invest in?
Nir Kalkstein invests primarily in Health Care, Machine Learning and Artificial Intelligence startups, most often at Seed and Series B stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Nir Kalkstein?
Public channels for Nir Kalkstein include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Nir Kalkstein last invest?
The most recent investment recorded for Nir Kalkstein closed in Mar 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
